Atlas Trials

Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Clinical trial NCT06792253 · RECRUITING

Trial details

NCT number
NCT06792253
Sponsor
BeBetter Med Inc
Status
RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Start date
2025-01-06
Primary completion
2028-12-31
Enrollment
416

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.